Company Expects Cash Burn Rate to Reach $4M to $5M in 2026
The Company anticipates that its cash burn rate may increase to approximately $4 million to $5 million per quarter in 2026 as it prepares for and initiates the TAVVE pivotal study.
Trade with 70% Backtested Accuracy
Analyst Views on NVNO
About NVNO
About the author
enVVeno Medical Receives FDA Approval for TAVVE Trial
- First IDE Approval: enVVeno Medical has received the first-ever IDE approval from the FDA to conduct the TAVVE® trial, evaluating its innovative enVVe® system aimed at providing the first effective treatment option for approximately 3 million U.S. patients suffering from severe Chronic Venous Insufficiency (CVI), marking a significant advancement in the treatment of deep venous diseases.
- Clinical Trial Scale: The TAVVE trial will be conducted in two phases, with the first phase enrolling 10 patients for a 30-day safety assessment, followed by a second phase enrolling 220 patients, with 165 receiving the enVVe valve and 55 in a control group, expected to provide critical safety and efficacy data to the FDA.
- Significant Market Potential: With U.S. healthcare costs exceeding $20 billion annually due to deep venous insufficiency, the introduction of the enVVe system not only addresses this substantial unmet clinical need but also opens up a multi-billion-dollar market opportunity for the company, enhancing its competitiveness in the medical device sector.
- Sufficient Funding for Operations: As of March 31, 2026, enVVeno has approximately $25 million in cash and investments, which is expected to fund operations into Q3 2027, providing financial support for the successful execution of the TAVVE trial.
enVVeno Medical Reports FY GAAP EPS of -$33.06 Amid Reverse Stock Split
- Poor Financial Performance: enVVeno Medical reported a FY GAAP EPS of -$33.06, indicating significant challenges in financial health that could lead to a decline in investor confidence.
- Reverse Stock Split Announcement: The company announced a reverse stock split aimed at boosting its share price to meet exchange listing requirements; however, this move failed to improve market sentiment, resulting in a 20% drop in share price.
- Negative Market Reaction: Following the reverse split, the stock price fell by 20%, reflecting investor concerns about the company's future prospects, which may impact its ability to raise capital and maintain market competitiveness.
- Need for Strategic Reevaluation: Given the current financial situation, the company must reassess its strategic direction to address ongoing losses and restore investor trust, ensuring sustainable growth in the future.
enVVeno Medical Approves 1-for-35 Reverse Stock Split, Reducing Shares to 655K
- Reverse Stock Split Decision: enVVeno Medical's board approved a 1-for-35 reverse stock split effective January 20, 2026, reducing outstanding shares from approximately 22.9 million to about 655,000, aiming to enhance share price and attract investor interest.
- Exchange Arrangement: Post-split, the company's common stock will resume trading on the Nasdaq Capital Market under the existing ticker symbol 'NVNO', indicating a strategic move to improve market perception and liquidity.
- Market Reaction: Following the reverse split announcement, enVVeno Medical's stock price fell 19.69% in premarket trading to $0.2761, reflecting negative market sentiment that could impact investor confidence.
- Shareholder Impact: The reverse split will consolidate every 35 shares into one, which may reduce the number of shares held by shareholders in the short term, but the company aims to improve long-term investment appeal through a higher share price.
Gold Drops More Than 2%; Cidara Therapeutics Stock Soars
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones falling 0.44%, while the NASDAQ and S&P 500 rose by 0.59% and 0.27%, respectively. Utilities shares increased slightly, but communication services stocks dropped by 1%.
Notable Company Performances: Spire Inc's shares fell over 2% after reporting larger-than-expected quarterly losses, while Cidara Therapeutics saw a 105% surge in shares following Merck's acquisition announcement.
Commodities Update: Oil prices rose by 1.9% to $59.81, while gold and silver prices fell by 2.2% and 5%, respectively. Copper also saw a decline of 1.1%.
Global Market Trends: European shares declined, with the STOXX 600 down 1.54%, and Asian markets mostly closed lower, highlighted by Japan's Nikkei 225 dropping 1.77%.
Nasdaq Falls by More Than 300 Points; Applied Materials Reports Positive Q4 Earnings
Market Performance: U.S. stocks opened lower, with the Dow down 1.21%, Nasdaq falling 1.51%, and S&P 500 decreasing by 1.17%. European and Asian markets also experienced declines.
Sector Movements: Real estate shares rose by 0.3%, while information technology stocks fell by 1.2%. Notable stock movements included Cidara Therapeutics surging 106% after a Merck acquisition announcement.
Company Earnings: Applied Materials reported better-than-expected fourth-quarter results and projected first-quarter revenue above estimates, while several companies, including Gauzy Ltd and enVVeno Medical Corp, faced significant stock declines.
Commodity Updates: Oil prices increased by 1.9% to $59.82, while gold and silver prices fell by 3.4% and 5%, respectively. Economic data on oil rig counts is expected to be released today.
RLX Technology Shares Rise 6%; Check Out 20 Stocks Making Moves in Premarket Trading
RLX Technology Inc Performance: RLX Technology's shares rose 6% to $2.47 in pre-market trading after reporting third-quarter earnings of 3 cents per share and $158.6 million in sales.
Notable Gainers: Cidara Therapeutics surged 92% to $203.50 following a significant ownership disclosure, while other companies like Binah Capital Group and Expion360 also saw substantial pre-market gains.
Significant Losers: TSS Inc experienced a 40.2% drop to $9.10 after reporting a year-over-year decline in financial results, with enVVeno Medical Corp and Nuvve Holding Corp also facing significant losses.
Market Overview: The pre-market trading session showed a mix of gains and losses among various stocks, reflecting varied financial performances and investor reactions to earnings reports.
enVVeno Medical Receives FDA Approval for TAVVE Trial
- First IDE Approval: enVVeno Medical has received the first-ever IDE approval from the FDA to conduct the TAVVE® trial, evaluating its innovative enVVe® system aimed at providing the first effective treatment option for approximately 3 million U.S. patients suffering from severe Chronic Venous Insufficiency (CVI), marking a significant advancement in the treatment of deep venous diseases.
- Clinical Trial Scale: The TAVVE trial will be conducted in two phases, with the first phase enrolling 10 patients for a 30-day safety assessment, followed by a second phase enrolling 220 patients, with 165 receiving the enVVe valve and 55 in a control group, expected to provide critical safety and efficacy data to the FDA.
- Significant Market Potential: With U.S. healthcare costs exceeding $20 billion annually due to deep venous insufficiency, the introduction of the enVVe system not only addresses this substantial unmet clinical need but also opens up a multi-billion-dollar market opportunity for the company, enhancing its competitiveness in the medical device sector.
- Sufficient Funding for Operations: As of March 31, 2026, enVVeno has approximately $25 million in cash and investments, which is expected to fund operations into Q3 2027, providing financial support for the successful execution of the TAVVE trial.
enVVeno Medical Reports FY GAAP EPS of -$33.06 Amid Reverse Stock Split
- Poor Financial Performance: enVVeno Medical reported a FY GAAP EPS of -$33.06, indicating significant challenges in financial health that could lead to a decline in investor confidence.
- Reverse Stock Split Announcement: The company announced a reverse stock split aimed at boosting its share price to meet exchange listing requirements; however, this move failed to improve market sentiment, resulting in a 20% drop in share price.
- Negative Market Reaction: Following the reverse split, the stock price fell by 20%, reflecting investor concerns about the company's future prospects, which may impact its ability to raise capital and maintain market competitiveness.
- Need for Strategic Reevaluation: Given the current financial situation, the company must reassess its strategic direction to address ongoing losses and restore investor trust, ensuring sustainable growth in the future.
enVVeno Medical Approves 1-for-35 Reverse Stock Split, Reducing Shares to 655K
- Reverse Stock Split Decision: enVVeno Medical's board approved a 1-for-35 reverse stock split effective January 20, 2026, reducing outstanding shares from approximately 22.9 million to about 655,000, aiming to enhance share price and attract investor interest.
- Exchange Arrangement: Post-split, the company's common stock will resume trading on the Nasdaq Capital Market under the existing ticker symbol 'NVNO', indicating a strategic move to improve market perception and liquidity.
- Market Reaction: Following the reverse split announcement, enVVeno Medical's stock price fell 19.69% in premarket trading to $0.2761, reflecting negative market sentiment that could impact investor confidence.
- Shareholder Impact: The reverse split will consolidate every 35 shares into one, which may reduce the number of shares held by shareholders in the short term, but the company aims to improve long-term investment appeal through a higher share price.
Gold Drops More Than 2%; Cidara Therapeutics Stock Soars
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones falling 0.44%, while the NASDAQ and S&P 500 rose by 0.59% and 0.27%, respectively. Utilities shares increased slightly, but communication services stocks dropped by 1%.
Notable Company Performances: Spire Inc's shares fell over 2% after reporting larger-than-expected quarterly losses, while Cidara Therapeutics saw a 105% surge in shares following Merck's acquisition announcement.
Commodities Update: Oil prices rose by 1.9% to $59.81, while gold and silver prices fell by 2.2% and 5%, respectively. Copper also saw a decline of 1.1%.
Global Market Trends: European shares declined, with the STOXX 600 down 1.54%, and Asian markets mostly closed lower, highlighted by Japan's Nikkei 225 dropping 1.77%.
Nasdaq Falls by More Than 300 Points; Applied Materials Reports Positive Q4 Earnings
Market Performance: U.S. stocks opened lower, with the Dow down 1.21%, Nasdaq falling 1.51%, and S&P 500 decreasing by 1.17%. European and Asian markets also experienced declines.
Sector Movements: Real estate shares rose by 0.3%, while information technology stocks fell by 1.2%. Notable stock movements included Cidara Therapeutics surging 106% after a Merck acquisition announcement.
Company Earnings: Applied Materials reported better-than-expected fourth-quarter results and projected first-quarter revenue above estimates, while several companies, including Gauzy Ltd and enVVeno Medical Corp, faced significant stock declines.
Commodity Updates: Oil prices increased by 1.9% to $59.82, while gold and silver prices fell by 3.4% and 5%, respectively. Economic data on oil rig counts is expected to be released today.
RLX Technology Shares Rise 6%; Check Out 20 Stocks Making Moves in Premarket Trading
RLX Technology Inc Performance: RLX Technology's shares rose 6% to $2.47 in pre-market trading after reporting third-quarter earnings of 3 cents per share and $158.6 million in sales.
Notable Gainers: Cidara Therapeutics surged 92% to $203.50 following a significant ownership disclosure, while other companies like Binah Capital Group and Expion360 also saw substantial pre-market gains.
Significant Losers: TSS Inc experienced a 40.2% drop to $9.10 after reporting a year-over-year decline in financial results, with enVVeno Medical Corp and Nuvve Holding Corp also facing significant losses.
Market Overview: The pre-market trading session showed a mix of gains and losses among various stocks, reflecting varied financial performances and investor reactions to earnings reports.
